Patents by Inventor Ludger Grosse-Hovest

Ludger Grosse-Hovest has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE
    Publication number: 20210128722
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Application
    Filed: September 17, 2020
    Publication date: May 6, 2021
    Inventors: Helmut SALIH, Ludger GROSSE-HOVEST, Andreas HERRMANN, Hans-Georg KOPP, Stefanie MAURER
  • RANKL-specific agent for treating metastatic disease
    Patent number: 10806786
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: October 20, 2020
    Assignee: Probiocon GmbH
    Inventors: Helmut Salih, Ludger Grosse-Hovest, Andreas Herrmann, Hans-Georg Kopp, Stefanie Maurer
  • Recombinant bispecific antibody binding to CD20 and CD95
    Patent number: 10590202
    Abstract: A bispecific antibody format, which comprises a) a Fab fragment comprising a first binding site for a first antigen; b) an scFv fragment comprising a second binding site for a second antigen; and c) a CH2 domain, wherein the Fab fragment and the scFv fragment are linked via the CH2 domain, wherein the first antigen is CD95 and the second antigen is CD20; or the first antigen is CD20 and the second antigen is CD95.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: March 17, 2020
    Assignee: BALIOPHARM AG
    Inventors: Andreas Herrmann, Ludger Grosse-Hovest
  • RECOMBINANT ANTIBODY MOLECULE AND ITS USE FOR TARGET CELL RESTRICTED T CELL ACTIVATION
    Publication number: 20180208657
    Abstract: The present disclosure relates to a recombinant antibody molecule, bispecific as well as tri-specific hetero-dimeric antibody molecules, as well as a method for producing the same, its use and a nucleic acid molecule encoding the recombinant antibody molecules. The disclosure in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.
    Type: Application
    Filed: August 11, 2015
    Publication date: July 26, 2018
    Inventors: Gundram JUNG, Helmut SALIH, Gernot STUHLER, Ludger GROSSE-HOVEST, Berit LOCHMANN
  • BISPECIFIC ANTIBODY MOLECULE
    Publication number: 20180057608
    Abstract: The present invention relates to a method of treating a disease. The method comprises administering to a patient in need thereof a recombinant bispecific antibody molecule consisting of a Fab fragment comprising a first binding site for a first antigen, a single chain Fv fragment comprising a second binding site for a second antigen and an immunoglobulin IgG1 CH2 domain.
    Type: Application
    Filed: June 27, 2017
    Publication date: March 1, 2018
    Inventors: Gundram Jung, Michael DURBEN, Ludger Grosse-Hovest
  • RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE
    Publication number: 20170319687
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 9, 2017
    Applicant: Probiocon GmbH
    Inventors: Helmut SALIH, Ludger GROSSE-HOVEST, Andreas HERRMANN, Hans-Georg KOPP, Stefanie RAAB
  • Bispecific antibody molecule
    Patent number: 9718893
    Abstract: The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: August 1, 2017
    Assignee: SYNIMMUNE GMBH
    Inventors: Gundram Jung, Michael Durben, Ludger Grosse-Hovest
  • RECOMBINANT BISPECIFIC ANTIBODY BINDING TO CD20 AND CD95
    Publication number: 20150274833
    Abstract: A bispecific antibody format, which comprises a) a Fab fragment comprising a first binding site for a first antigen; b) an scFv fragment comprising a second binding site for a second antigen; and c) a CH2 domain, wherein the Fab fragment and the scFv fragment are linked via the CH2 domain, wherein the first antigen is CD95 and the second antigen is CD20; or the first antigen is CD20 and the second antigen is CD95.
    Type: Application
    Filed: November 19, 2013
    Publication date: October 1, 2015
    Inventors: Andreas Herrmann, Ludger Grosse-Hovest
  • Anti-FLT3 antibodies
    Patent number: 9023996
    Abstract: The present invention relates to anti-FLT3 antibodies with a modified Fc region comprising the amino acid substitutions 239D and 332E to enhance antibody-dependent cell cytotoxicity (ADCC) of these antibodies. The invention further relates to pharmaceutical compositions containing these antibodies, nucleic acids encoding these antibodies as well as methods of using such antibodies.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: May 5, 2015
    Assignee: Synimmune GmbH
    Inventors: Ludger Grosse-Hovest, Hans-Joerg Buehring, Martin Hofmann, Steffen Aulwurm, Grundram Jung
  • BISPECIFIC ANTIBODY MOLECULE
    Publication number: 20150119555
    Abstract: The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.
    Type: Application
    Filed: November 12, 2012
    Publication date: April 30, 2015
    Applicant: SYNIMMUNE GMBH
    Inventors: Gundram Jung, Michael Durben, Ludger Grosse-Hovest
  • BI-SPECIFIC ANTIBODIES FOR MEDICAL USE
    Publication number: 20140314764
    Abstract: A bispecific antibody format devoid of an active Fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on B-cells, for use in the treatment or prevention of B cell mediated autoimmune diseases.
    Type: Application
    Filed: November 19, 2012
    Publication date: October 23, 2014
    Inventors: Gundram Jung, Ludger Grosse-Hovest
  • ANTI-FLT3 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20120328612
    Abstract: The present invention relates to anti-FLT3 antibodies with a modified Fc region comprising the amino acid substitutions 239D and 332E to enhance antibody-dependent cell cytotoxicity (ADCC) of these antibodies. The invention further relates to pharmaceutical compositions containing these antibodies, nucleic acids encoding these antibodies as well as methods of using such antibodies.
    Type: Application
    Filed: December 23, 2010
    Publication date: December 27, 2012
    Inventors: Ludger Grosse-Hovest, Hans-Joerg Buehring, Martin Hofmann, Steffen Aulwurm, Grundram Jung